1 Clinical features and outcomes of hospitalised patients with COVID-19 and

2 Parkinsonian disorders: a multicentre UK-based study

3

4	Lexy Sorrell ¹ ¶* and Valentina Leta ^{2,3} ¶, Anton Barnett ¹ , Kara Stevens ⁴ , Angela King ¹ , Jemma					
5	Inc	ches ^{1,5} , Christopher Kobylecki ^{6,7} , Richard Walker ^{8,9} , K Ray Chaudhuri ^{2,3} , Hannah Martin ¹⁰ ,				
6	Jane Rideout ¹¹ , J Robert Sneyd ¹¹ , Sarah Campbell ¹ , Camille Carroll ^{1,5} on behalf of the					
7	CC	OVID-19 PD UK study team [^]				
8						
9	1.	University of Plymouth, Plymouth, United Kingdom.				
10	2.	King's College London, Institute of Psychiatry, Psychology & Neuroscience, Department				
11		of Basic and Clinical Neuroscience; London, United Kingdom.				
12	3.	Parkinson's Foundation Centre of Excellence, King's College Hospital; London, United				
13		Kingdom.				
14	4.	Exploristics Ltd, Belfast, Northern Ireland, United Kingdom.				
15	5.	University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom.				
16	6.	Division of Neuroscience and Experimental Psychology, Manchester Academic Health				
17		Science Centre, University of Manchester, Manchester, United Kingdom.				
18	7.	Department of Neurology, Manchester Centre for Clinical Neurosciences, Northern Care				
19		Alliance NHS Foundation Trust, Stott Lane, Salford, United Kingdom.				
20	8.	Department of Medicine, North Tyneside Hospital, Northumbria Healthcare NHS				
21		Foundation Trust, Rake Lane, North Shields, United Kingdom.				
22	9.	Population Health Science Institute, Newcastle University, Newcastle, United Kingdom.				
23	10	. University Hospitals Coventry and Warwickshire NHS Trust, United Kingdom.				
24	Ц	Expert by Experience. TE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.				

1

25 * Corresponding Author

- 26 Email: lexy.sorrell@plymouth.ac.uk (LS)
- 27 These authors are to be considered joint first authors.
- 28 ^A complete list of the COVID-19 PD UK study team is provided in S1 Supporting information.

29 Abstract

Background: Parkinson's disease has been identified as a risk factor for severe Coronavirus
disease 2019 (COVID-19) outcomes. However, whether the significant high risk of death from
COVID-19 in people with Parkinson's disease is specific to the disease itself or driven by other
concomitant and known risk factors such as comorbidities, age, and frailty remains unclear.

Objective: To investigate clinical profiles and outcomes of people with Parkinson's disease and
 atypical parkinsonian syndromes who tested positive for COVID-19 in the hospital setting in
 a multicentre UK-based study.

Methods: A retrospective cohort study of Parkinson's disease patients with a positive COVID19 test admitted to hospital between February 2020 and July 2021. An online survey was used
to collect data from clinical care records, recording patient, Parkinson's disease and COVID19 characteristics. Associations with time-to-mortality and severe outcomes were analysed
using either the Cox proportional hazards model or logistic regression models, as appropriate.

Results: Data from 552 admissions were collected: 365 (66%) male; median (inter-quartile range) age 80 (74-85) years. The 34-day mortality rate was 38.4%; male sex, increased age and frailty, Parkinson's dementia syndrome, requirement for respiratory support and no vaccination were associated with increased mortality risk. Community-acquired COVID-19 and co-morbid chronic neurological disorder were associated with increased odds of requiring respiratory support. Hospital-acquired COVID-19 and delirium were associated with requiring an increase in care level post-discharge.

Conclusions: This first, multicentre, UK-based study on people with Parkinson's disease or
atypical parkinsonian syndromes, hospitalised with COVID-19, adds and expands previous
findings on clinical profiles and outcomes in this population.

3

- 52 Keywords: Parkinson's disease, parkinsonism, parkinsonian disorders, COVID-19, inpatients,
- 53 comorbidity, mortality, length of stay.

54 Introduction

The Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory 55 syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide since early 2020 with 56 unprecedented speed (1). Clinical risk prediction models have been developed to identify risks 57 of poor short-term outcomes due to the SARS-CoV-2 infection (mortality and hospital 58 admission) and offer guidance to public health policymakers for clinical decision-making 59 processes, prioritisation for vaccination, and targeted recruitment for clinical trials. Among 60 them, the QCovid and the more recently developed QCovid3 risk algorithms, have identified 61 Parkinson's disease (PD) as a risk factor for severe COVID-19 outcomes, despite vaccination 62 (adjusted cause-specific hazard ratios for COVID-19 death after vaccination of 2.23 (1.79 to 63 2.78)) (2, 3). Advanced age, frailty and impaired cough reflex are commonly observed in 64 65 people with PD (PwP) and might contribute to their susceptibility to developing severe acute respiratory syndrome (4). A variety of studies have investigated mortality in PwP and COVID-66 67 19 with figures ranging from 5% to 100% (5); the wide range reflects the heterogeneity of methodologies used (case report, series, surveys, retrospective or prospective cohort studies) 68 and cohort analysed (home-based vs hospitalised patients, early vs advanced patients, etc.) (6-69 18). However, whether the significant high risk of death from COVID-19 in PwP is specific to 70 PD itself or driven by other concomitant and known risk factors such as comorbidities 71 (hypertension, diabetes, pulmonary disease, obesity, immunosuppression, and dementia), older 72 age (>60 years), and frailty remains unclear (5). The COVID-19 PD study is the first to 73 investigate the association of demographic, co-morbidity, COVID-19 and PD-specific factors 74 with mortality and severe outcomes of inpatients with PD and atypical parkinsonian syndromes 75 (APS) who tested positive for COVID-19 admitted to a UK NHS trust hospital. 76

77 Methods

78 Study design and population

The COVID-PD UK study was a retrospective cohort study across 21 acute care settings in England funded by Parkinson's UK (Ref: G-2001). Approvals were obtained from the University of Plymouth Faculty Research Ethics and Integrity Committee (Ref: 2269) and the Health Research Authority (IRAS ID 285686). Members of the project team included PwP who were involved in all aspects of protocol and study development.

The study consisted of patients with a clinical diagnosis of PD, APS (including progressive supranuclear palsy, multiple system atrophy) or Parkinson's dementia syndrome (Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB)) admitted to participating hospitals between 5th February 2020 and 31st July 2021, with a positive polymerase chain reaction (PCR) test. Exclusion criteria were patients with a diagnosis of vascular parkinsonism and a COVID-19 positive test over 2 weeks prior to admission or at any time following discharge.

Clinical care teams completed an online survey on JISC (<u>https://www.onlinesurveys.ac.uk/</u>)
using patients' clinical care records, extracting information from admission to at least 28-days
following admission. Retrospective data collection began in February 2021 and the online
survey closed on the 31st July 2021. Individuals were pseudo-anonymised by sites to allow for
data clarification where required.

Data included patient, PD and COVID-19 related characteristics along with details of
admission, discharge and participation in a COVID-19 related clinical trial. Comorbidities were
chosen to allow comparison with the International Severe Acute Respiratory and emerging
Infection Consortium (ISARIC) study of hospitalised COVID-19 patients in the UK (19).
Patient characteristics included age, sex, ethnicity, index of multiple deprivation (IMD),

101 location pre-admission and clinical frailty score (CFS) (20). PD related features captured 102 included those considered neurological risk features in UK national guidance (21), such as 103 significant cognitive impairment or psychosis, bulbar symptoms, significant respiratory 104 compromise, significant autonomic neuropathy, as well as marked motor fluctuations and 105 Hoehn and Yahr (H&Y) stage. PD features and comorbidities could be entered as unknown by 106 site staff on the JISC survey. No imputation of missing data was performed, however, sites 107 were asked to address unexpected responses and missing data during the querying process.

The wave of positive COVID-19 test was identified. Wave one: 23/03/2020 to 30/05/2020, corresponding to wild-type SARS-CoV2, and wave two: 07/09/2020 to 22/05/2021 (22) corresponding to the emergence of alpha and delta variants in the (23).

Patients were classified as vaccinated if their positive COVID-19 test was over 14 days following their first vaccine dose. COVID-19 was classified as hospital-acquired if the positive COVID-19 test was more than 5 days following admission; otherwise, COVID-19 was classified as community-acquired.

115 COVID-19 and non-COVID-19 symptoms at admission were recorded as free text and 116 subsequently grouped by the research team into categories including altered mental state 117 (delirium, confusion, obtundation, reduced oral intake), COVID-19 (pyrexia, cough, anosmia) 118 and other respiratory symptoms. Symptoms were summarised for the community- and hospital-119 acquired COVID-19 patients separately.

The primary outcome of the study was death within 28-days of a COVID-19 positive test. Date of death was recorded as the Sunday following death to preserve anonymity. We therefore used death within 34-days as a proxy outcome; this assumption was explored in a sensitivity analysis. Secondary outcomes included the requirement for respiratory support, an increase in the level of care post-discharge and change in levodopa equivalent daily dose (LEDD).

125 Statistical methods

A summary of the data is presented using frequency and percentages for categorical variables of the non-missing sample, while means, standard deviations, medians and ranges are presented for continuous variables. Values entered as 'unknown' were coded to missing to ease the comparison between presence and absence of characteristics and due to the small group sizes of some unknown categories.

Survival within 34-days of a COVID-19 positive test was analysed using univariable and 131 multivariable Cox proportional hazards models, using Schoenfeld's test to assess the 132 assumption of proportional hazards. The requirement for respiratory support and an increase in 133 care were modelled using univariable and multivariable logistic regression models. Model 134 135 selection for the final multivariable models was conducted using backward elimination, whilst including variables of clinical interest: sex, age, ethnicity, diagnosis, wave of COVID-19 136 positive test and where COVID-19 was acquired, regardless of their statistical significance. For 137 each outcome, the first-order interaction of wave and where COVID-19 was acquired was 138 examined for statistical significance. In the multivariable models, site was included as a random 139 effect to account for potential differences in practice and COVID-19 severity between UK 140 regions during the pandemic. 141

142 Change in LEDD was found to occur in less than 25% of discharged individuals and was143 therefore analysed descriptively.

Sensitivity analyses were conducted for all outcomes using individuals with a positive COVID19 test in wave two, sites that comprehensively selected their patients to enter over waves one
and two and for the survival outcome, censoring at 28-days.

8

147 All analyses are presented with 95% confidence intervals and all tests are two-sided, where a

- p-value of < 0.05 is considered statistically significant. All analyses were conducted using R
- version 4.1.3 (24) using packages including survival (25), glmmTMB (26) and forester (27).

150 **Results**

Site staff from 21 hospitals entered 627 individual data sets; of these 17 were duplicates, 38 were excluded due to unverifiable data and 20 were excluded due to meeting the exclusion criteria. The final number of individual admission data sets included in the COVID-19 PD study was 552 compromising 385 community-acquired and 167 hospital-acquired COVID-19 infection episodes; the timing of these admissions is shown in Figure 1. Six sites entered data comprehensively over waves one and two (n=242), while due to resource constraints, the other sites submitted data for one of the two waves or entered data from a selection of patients.

158 Figure 1: Positive COVID-19 cases captured in the COVID-19 PD study (red bar chart, left

159 *y-axis) by month, overlaid by UK daily COVID-19 hospital admissions (28) (blue line graph,*

160 right y-axis). Grey regions reflect COVID-19 wave one (23/03/2020 - 30/05/2020) and wave

161 *two* (07/09/2020 - 22/05/2021) *in the UK.*

162 Demographics and comorbidities

Patient demographics and diagnosis of parkinsonian syndrome details are presented in Table 163 1. The majority of the patients had PD (349/552 (63.2%)), with 170/552 (30.8%) having 164 PDD/DLB). Only 33 (6.0%) of patients had APS. The median (interquartile range (IQR)) age 165 at admission was 80 (74-85) years with 73.6% of patients over the age of 75 years; APS patients 166 were younger (median (IQR) 75 (70-78) years), while 365/552 (66.1%) were male. The 167 majority of patients were White British (476/552 (86.2%)); further details of the sample 168 ethnicity can be found in Table S2.1 (see S2 Supporting information). Thirty-two patients were 169 enrolled into COVID-19 therapeutic clinical trials, including 21 in the RECOVERY trial (29). 170

- 171 Further information on Parkinson's and COVID-19 characteristics is provided in Tables S2.1
- to S2.3 (see S2 Supporting information).

- 173 Table 1: Patient demographics by diagnosis of Parkinson's disease (n=349), Parkinson's dementia
- 174 syndrome (n=170) and Atypical Parkinsonian syndrome (n=33). For further breakdown of ethnicity,
- see Table S2.1 (see S2 Supporting information). Abbreviations: Levodopa equivalent daily dose
- 176 *(LEDD), Index of multiple deprivation (IMD).*

		Parkinson's	Parkinson's dementia	Atypical parkinsonian	Total	
		disease	syndrome	syndrome		
	N (% of total)	349 (63.2)	170 (30.8)	33 (6.0)	552 (100.0)	
	Ν	349	170	33	552	
Age at admission (years)	Median (IQR)	81 (74-86)	81 (76-85)	75 (70-78)	80 (74-85)	
	[Min., Max.]	[43, 99]	[65, 101]	[45, 98]	[43, 101]	
	N	339	168	33	540	
Disease duration (years)	Median (IQR)	5 (3-9)	5 (3-9)	2 (1-4)	5 (2-9)	
	[Min., Max.]	[0, 27]	[0, 29]	[0, 11]	[0, 29]	
	Ν	340	169	33	542	
LEDD (mg)	Median (IQR)	450 (300-653)	375 (150-575)	200 (0-400)	400 (243-615)	
	[Min., Max.]	[0, 2313]	[0, 2300]	[0, 800]	[0, 2313]	
Sex	N	349	170	33	552	
Male	NI (0/)	224 (64.2)	120 (70.6)	21 (63.6)	365 (66.1)	
Female	IN (70)	125 (35.8)	50 (29.4)	12 (36.4)	187 (33.9)	
Ethnicity	Ν	349	170	33	552	
White British		298 (85.4)	152 (89.4)	26 (78.8)	476 (86.2)	
Asian/British Asian (Indian)		10 (2.9)	3 (1.8)	2 (6.1)	15 (2.7)	
White (any other background)	N (%)	10 (2.9)	2 (1.2)	1 (3.0)	13 (2.4)	
Asian/British Asian (Pakistani)		5 (1.4)	1 (0.6)	0 (0.0)	6 (1.1)	
Other		26 (7.4)	12 (7.1)	4 (12.0)	42 (7.6)	
Hoehn and Yahr	N	322	167	32	521	
1-2		49 (15.2)	5 (3.0)	0 (0.0)	54 (10.4)	
2.5-3	N (%)	125 (38.8)	41 (24.6)	8 (25.0)	174 (33.4)	
4-5		148 (46.0)	121 (72.5)	24 (75.0)	293 (56.2)	
Clinical frailty score	N	345	167	33	545	
<5		75 (21.6)	3 (1.8)	3 (9.1)	81 (14.8)	
5-6	N (%)	170 (49.3)	71 (42.5)	14 (42.4)	255 (46.8)	
7-9		100 (29.0)	93 (55.7)	16 (48.5)	209 (38.3)	
Location pre-admission	N	349	170	33	552	
Local/community hospital		3 (0.9)	3 (1.8)	1 (3.0)	7 (1.3)	
Own Home/private residence	N (%)	268 (76.8)	97 (57.1)	24 (72.7)	389 (70.5)	
Residential or nursing home		78 (22.3)	70 (41.2)	8 (24.2)	156 (28.3)	
IMD decile	N	349	170	33	552	
1-2		63 (18.1)	28 (16.5)	5 (15.2)	96 (17.4)	
3-4		77 (22.1)	23 (13.5)	4 (12.1)	104 (18.8)	
5-6	N (%)	77 (22.1)	37 (21.8)	9 (27.3)	123 (22.3)	
7-8		69 (19.8)	38 (22.4)	8 (24.2)	115 (20.8)	
9-10		63 (18.1)	44 (25.9)	7 (21.2)	114 (20.7)	

177

More patients hospitalised with positive COVID-19 tests had community-acquired rather than
hospital-acquired COVID-19 in both wave one (153/190 (80.5%)) and wave two (220/343
(64.1%)).

509/552 (92.2%) had at least one reported co-morbidity at admission, the most frequently
reported being hypertension (251/542, 46.3%), dementia (218/535 (40.7%)), chronic cardiac
disease (193/539 (35.8%)) and chronic kidney disease (117/535 (21.9%)) (see Table S2.1, S2
Supporting information).

185 Parkinsonian syndrome-related features

186 349/552 (63.2%) patients had PD, 170/552 (30.8%) had PDD/DLB and 33/552 (6.0%) patients

had an atypical parkinsonian syndrome. Overall, 251/535 (46.9%) of the cohort had significant

cognitive impairment and 154/493 (31.2%) had marked motor fluctuations. Bulbar symptoms

189 were most common in APS patients (16/32 (50.0%) vs. 49/331, (14.8%) and 33/160 (20.6%)

190 for PD and PDD/DLB, respectively) (see Figure 2 and Table S2.2, S2 Supporting information).

191 Patients with PDD/DLB and APS more often had pre-morbid Hoehn and Yahr stages 4-5

192 (121/167 (72.5%) and 24/32 (75.0%), respectively) compared to PD patients (148/322 (46.0%)).

193 *Figure 1: Clinical features of Parkinson's as a proportion by diagnosis of Parkinson's disease.*

194 X-axis: proportion of feature within diagnosis. Abbreviations: Parkinson's disease (PD),

195 *Parkinson's dementia syndrome (PDD/DLB) and atypical parkinsonian syndrome (APS).*

196 Symptoms of COVID-19

The frequency of altered mental state and classical COVID-19 or respiratory symptoms for community- and hospital-acquired COVID-19 patients are presented in Figures 3A and 3B, respectively. Of patients with community-acquired COVID-19, 7.0% (27/385) had neither altered mental state nor classical COVID-19 or respiratory symptoms. This was the case in 25.1% (42/167) of the hospital-acquired COVID-19 patients. Altered mental state was the only

feature of COVID-19 infection in 15/385 (3.9%) of community-acquired and 16/167 (9.6%) of
hospital-acquired cases.

- 204 *Figure 3: Frequency of altered mental state and classic COVID-19 or respiratory symptoms*
- 205 by where COVID-19 was acquired. A: The frequency of community acquired COVID-19
- 206 patients (total n=385) by symptoms of altered mental state, classic COVID-19 or other
- 207 respiratory symptoms during admission). B: The frequency of hospital acquired COVID-19
- 208 patients (total n=167) with the symptoms of altered mental state and classic COVID-19 or
- 209 respiratory symptoms (mild symptoms or respiratory support) associated with their COVID-
- 210 *19 infection*.

211 Length of stay

- 212 The time from positive test to discharge of patients who acquired COVID-19 in the community was shorter compared to those who acquired COVID-19 in hospital Error! Reference source 213 not found.(median (IQR) of 12 (7-21) and 16 (5-28) days, respectively). For those discharged, 214 84% of community-acquired patients were discharged by day 28 compared to 75% of hospital-215 acquired patients (Figure 4). Time until discharge was longer for those with bulbar symptoms 216 217 (median (IQR) of 17 (8-27) compared to 13 (6-23)), a chronic neurological disorder (19 (10-31) compared to 12 (6-22)), those in wave two compared to wave one (15 (6-27) and 12 (7-218 19), respectively) and those with delirium (15 (7-29) compared to 12 (6-21)). Time until 219 220 discharge for further patient, COVID-19 and PD characteristics are detailed in Table S2.4 (see S2 Supporting information). 221
- Figure 4: Density plot of time to discharge or death from first positive COVID-19 test by place
 of COVID-19 acquisition (community or hospital). Two patients that remained in hospital
 following the study period have been omitted.
- 225 **Outcomes**

226 *Mortality*

Details of patient outcomes and discharge are provided in Table S2.5 (see S2 Supporting
information). Of the 552 patients in the COVID-19 PD study, 212 (38.4%) died within 34-days
of a COVID-19 positive test. Of these patients, 85.4% (181/212) died in hospital, 9.0%
(19/212) died following discharge and 5.7% (12/212) died having been discharged to end-oflife care.

Univariable and multivariable results of the Cox models for mortality are provided in Table 232 S3.1 (see S3 Supporting information), along with the results from each sensitivity analysis. The 233 results of the multivariable Cox proportional hazards model are presented in a forest plot in 234 Figure 5. Increased risk of mortality within 34-days was associated with increased age (hazard 235 236 ratio (HR) 1.05, with a 95% confidence interval (CI) 1.03 to 1.07) and PDD/DLB (HR 1.59 237 with 95% CI 1.14 to 2.20, reference: PD), after adjustment. Decreased risk of mortality was associated with female sex (HR 0.54, with a 95% CI 0.39 to 0.75), a pre-morbid CFS of <5238 239 (HR 0.62, with a 95% CI 0.44 to 0.85, reference: 7-9), being vaccinated (HR 0.36, with a 95% CI 0.13 to 0.99) and having asymptomatic or mild respiratory COVID-19 symptoms (HR and 240 95% CI: 0.22, 0.12 to 0.39 and 0.27, 0.18 to 0.41, respectively, reference: respiratory support). 241 No association was found after adjustment between mortality within 34-days and any other PD 242 or COVID-19 features. 243

244 *Figure 5: Forest plot of the multivariable Cox proportional hazards model of mortality*

within 34-days of a COVID-19 positive test. Abbreviations: confidence interval (CI).

As the date of the Sunday following death was captured during the study as a proxy for date of death, all patients included in the primary analysis have been censored at 34-days, with eight patients dying between days 28 and 34. We have conducted a sensitivity analysis investigating

the effect of 28-day censoring; all sensitivity analyses found no substantial changes to the final
mortality model (see Table S3.1, S3 Supporting information).

251 *Requirement for respiratory support*

Nine patients (1.6%) in the study were admitted to high-dependency care (HDU) or intensive
care units (ICU). Over half of patients received respiratory support while in hospital (291/552,
52.7%) with the majority of these (266/291, 91%) receiving oxygen supplementation; 28.3%
(156/552) had mild symptoms not requiring support and 19.0% (105/552) were asymptomatic
from a respiratory perspective. Patients with asymptomatic and mild symptoms were combined
to compare the odds of requiring respiratory support.

A forest plot presenting the results of the multivariable model is shown in Figure 6 (details of 258 259 univariable and sensitivity analyses in Table S3.2, S3 Supporting information). Increased odds of requiring respiratory support were found to be associated with presence of a co-morbid 260 chronic neurological disorder (odds ratio (OR) 1.81, with a 95% CI 1.06 to 3.09) and 261 community-acquired COVID-19 (OR of hospital-acquired 0.54, with a 95% CI 0.36 to 0.81, 262 reference: community) after adjustment. Sex, age, ethnicity and Parkinsonian syndrome 263 264 diagnosis were not found to be associated with requiring respiratory support. Sensitivity analyses found no substantial changes to the multivariable model. 265

Figure 6: Forest plot of the multivariable logistic regression model of the requirement for
respiratory support. Abbreviations: confidence interval (CI).

268 *Increase in care requirement post-discharge*

Increase in care was determined by change in location between admission and discharge, calculated for patients living at home prior to admission who were discharged from hospital. Of these 264 patients, 115 individuals (43.6%) had an increase in care and 149 (56.4%) remained at their pre-admission location at discharge. Results of the analysis are provided in

- Table S3.3 (see S3 Supporting information), while a forest plot of the multivariable results is
- provided in Figure 7. Increase in level of care post-discharge was associated with delirium
- associated with COVID-19 infection (OR 2.07, with a 95% CI 1.48 to 3.86) and hospital-
- acquired COVID-19 (OR 2.01, with a 95% CI 1.10 to 3.65).
- 277 Figure 7: Forest plot of the multivariable logistic regression model of an increase in care
- 278 post-discharge for patients admitted from their own home. Delirium is considered as delirium
- associated with COVID-19 infection. Abbreviations: confidence interval (CI).
- 280 *Change in levodopa equivalent daily dose*
- 281 Change in LEDD (mg) was calculated for the 359 individuals who were discharged and had
- both admission and discharge medication documented. There was no change in LEDD between
- admission and discharge for 76.0% of individuals (273/359), while 13.4% (48/359) had a
- decrease in LEDD and 10.6% (38/359) had an increase in LEDD. We observed no indication
- of an association between variables of clinical interest, diagnostic category and change in
- 286 LEDD.

287 **Discussion**

This is the first multicentre UK-based study to investigate demographics, comorbidities, 288 clinical profiles and outcomes of PwP and APS who tested positive for COVID-19 in the 289 hospital setting. The most common clinical presentations of COVID-19 in PwP and APS with 290 community- and hospital-acquired COVID-19 were classic COVID-19 or respiratory 291 symptoms and altered mental state. Comorbidities frequently reported were hypertension, 292 dementia, chronic cardiac disease, and chronic kidney disease with an overall 34-day mortality 293 rate of 38.4%. Increased age, male sex and diagnosis of PDD/DLB were associated with 294 increased risk of mortality, while low pre-morbid CFS (<5), being vaccinated, and 295 asymptomatic COVID-19 or mild respiratory symptoms were associated with reduced risk of 296 mortality. Finally, while increased risk of requiring respiratory support was associated with 297 298 presence of a co-morbid chronic neurological disorder and community-acquired COVID-19, patients with hospital-acquired COVID-19 and delirium required a higher level of care at 299 300 discharge. Overall, our study extends previous findings on clinical features and outcomes of hospitalised PwP and APS with COVID-19. 301

302 In relation to demographics, our cohort of parkinsonian patients had a median age at admission of 80 years which was higher than one of the cohorts of hospitalised non-parkinsonian patients 303 with COVID-19 (19). Of note, 73.4% (256/349) of our cohort of PD patients were over the age 304 of 75 years compared to 56.3% of the estimated PD population in England (30). Our cohort 305 included more male (66.1%) than female (33.9%) patients. Overall, these results are in line 306 with known increased prevalence of PD in the elderly and in men (11, 12, 31, 32), as well as 307 308 older age and male sex being risk factors for hospitalisation with COVID-19 generally (19, 33). 309

PD patients in our study were more frequently in the advanced motor phases of the disease
(46% H&Y 4-5) than the general PD population (16.4% H&Y 4-5 (34)), although with similar

prevalence of significant cognitive impairment (23.0% vs 24-31% in PD in the community 312 (35)) and marked motor fluctuations (27.5% vs 29% in PD in the community (36)). In relation 313 to frailty, which is known to be strongly associated with PD and mortality (37, 38), 78.3% of 314 PD patients in our study were pre-morbidly frail (CFS \geq 5), which is higher than a previously 315 reported proportion of PwP with frailty in an ambulant community PwP population (33%) (39). 316 Our finding is similar to previously reported levels of frailty in hospitalised PwP, where it has 317 318 been found to predict mortality (40). Patients within our study were found to have an increased level of frailty compared to the reported cohorts of patients hospitalised with COVID-19 319 320 generally (41-43).

Irrespective of the modality of infection (hospital or community-acquired), the most common 321 clinical presentations in our cohort of hospitalised parkinsonian patients with COVID-19 were 322 classic COVID-19 symptoms including fever, shortness of breath, hyposmia and cough or 323 respiratory symptoms in agreement with previous findings in the general population and in 324 PwP (12, 19). However, we found 49.6% of community-acquired and 38.3% of hospital-325 acquired COVID-19 infections in our cohort also had altered mental state, with no respiratory 326 symptoms in 3.9% and 9.6% respectively. Patients with altered mental state associated with 327 COVID-19 were more likely to require increased care on discharge in our study. This aligns 328 with findings from a single-centre study on hospitalised patients with COVID-19, where 329 330 patients with delirium were less likely to be discharged home, and more frequently discharged to other hospitals, nursing homes or rehabilitation institutes (44). Inconsistent results on the 331 contribution of delirium to mortality in COVID-19 have been published (45), and our data 332 supports a lack of association. Although altered mental state is a common neurological 333 manifestation of COVID-19 in hospitalised patients in general (up to 32%) (46-48), our data 334 suggests that hospitalised PwP or APS and COVID-19 present more frequently with altered 335 mental state than the general population, in line with previous findings and as expected in a 336

population of patients with known central nervous system neurodegeneration (11). Cognitive
impairment is frequently observed in PwP and APS and represents a well-known risk factor for
development of delirium (49).

In our study, the most frequently reported comorbidities at admission were hypertension 340 (46.3%), dementia (40.6%), chronic cardiac disease (35.8%), and chronic kidney disease 341 (21.9%). These results only partly mirror those of the ISARIC study (19), which was based on 342 UK hospitalised patients with COVID-19, where only 13.5% of patients were reported with 343 dementia. This discrepancy might be due to the fact that cognitive impairment is an intrinsic 344 feature of PD and APS as previously mentioned (49); in addition, our cohort included 170 345 patients with PDD/DLB who present with dementia as per diagnostic criteria (50). It is also 346 worth mentioning that most PwP are non-smokers, which can partly explain the lower 347 prevalence of chronic pulmonary disease in our cohort of patients than in the ISARIC study 348 (51). 349

In relation to length of stay, the median time from positive test to discharge in our study was 12 and 16 days for patients with community- and hospital-acquired COVID-19, respectively, which is longer than data from other UK, US and Iranian cohorts (median hospital stay of 5, 10 and 7 days, respectively) (8, 11, 52) reflecting possible differences in study methodology, health care settings, spatial and temporal spread of the pandemic as well as intrinsic features of the study populations.

Our study showed an overall 34-day mortality rate of 38.4% which is in line with data deriving from other US and European cohorts of hospitalised PD patients with COVID-19 of 35.8% and 35.4%, respectively (12, 53). These mortality rates appear to be higher compared with data from the general population with COVID-19 hospitalised over the same period (overall mortality rate of 25%) (54), adding to the evidence that PwP have a significant risk of poor

outcomes (5). Risk factors for increased mortality in our study were increased age, male sex and diagnosis of PD dementia while protective factors were low CFS (<5), being vaccinated, and COVID-19 with no or mild respiratory symptoms, in agreement with the literature on the general population and PD patients (3, 12, 19).

PwP/APS were more likely to require respiratory support if they had community-acquired COVID-19 or a co-morbid chronic neurological disorder. In our study, requirement for respiratory support was collected as a measure of severity of respiratory COVID-19. This might have unintentionally excluded individuals with worse respiratory COVID-19 than mild symptoms but did not have respiratory support available to them. Alternatively, there may have been individuals with mild symptoms that did not require respiratory support but received it as a precaution.

We found that patients with hospital-acquired COVID-19 and delirium had increased risk of a requiring a higher level of care at discharge (residential or nursing home or a local hospital). Development of delirium can signpost the presence of an underlying cognitive impairment which might become manifest during the infection and hospitalisation and, ultimately, have a detrimental effect on autonomy in performing activities of daily living (55).

Limitations of the study include the retrospective nature of the survey, perhaps contributing to the level of unknown or missing responses. Limited data on patients from diverse ethnicities were available and, therefore, we were unable to compare risks of poor COVID-19 outcomes between specific ethnic groups. The small number of APS patients limited our ability to evaluate outcomes within this group. COVID-19 testing policy in the UK changed during the course of the study and testing of asymptomatic patients and routine testing of hospital inpatients was uncommon during wave one; however, to account for the change in testing we

20

- have adjusted for wave in each model and conducted sensitivity analyses focused on wave two
- only, where we observed no substantial changes to any outcomes.

386 Conclusion

In this first, multicentre, UK-based study we found that, compared with published data on

- 388 COVID-19 admissions, PwP or APS hospitalised with COVID-19 have increased mortality
- and are more likely to require an increase in care level post-discharge. These findings may be
- attributable to an increased proportion of PwP/APS having dementia and cardiovascular co-
- morbidities, with COVID-19-associated delirium. PwP admitted with COVID-19 were older
- than community-dwelling PwP/APS, with more advanced Parkinson's and higher pre-morbid
- frailty. Our study expands previous findings on clinical profiles and outcomes of hospitalised
- 394 PwP and APS with COVID-19.

395 Acknowledgements

- 396 The views expressed are those of the authors and not necessarily those of the NHS, NIHR or
- 397 Department of Health. The authors acknowledge the support of Parkinson's UK who funded
- the study, the sponsor and the clinical and research teams who contributed to the study.

399 **References**

- Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health
 concern. Lancet. 2020;395(10223):470-3.
- Clift AK, Coupland CAC, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, et al.
 Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from
- 404 coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020:371:m3731.
- 4053.Hippisley-Cox J, Coupland CA, Mehta N, Keogh RH, Diaz-Ordaz K, Khunti K, et al. Risk
- 406 prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination:
 407 national prospective cohort study. BMJ. 2021;374.
- 408 4. Sulzer D, Antonini A, Leta V, Nordvig A, Smeyne RJ, Goldman JE, et al. COVID-19 and
 409 possible links with Parkinson's disease and parkinsonism: from bench to bedside. NPJ Parkinsons Dis.
 410 2020;6:18.
- 5. Fearon C, Fasano A. Prevalence and outcomes of Covid-19 in Parkinson's disease: Acute
 settings and hospital. Int Rev Neurobiol. 2022;165:35-62.
- Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's Disease Patients Affected
 by COVID-19. Mov Disord. 2020;35(6):905-8.

415 7. Fasano A, Elia AE, Dallocchio C, Canesi M, Alimonti D, Sorbera C, et al. Predictors of COVID-19 outcome in Parkinson's disease. Parkinsonism Relat Disord. 2020;78:134-7. 416 417 Fathi M, Taghizadeh F, Mojtahedi H, Zargar Balaye Jame S, Markazi Moghaddam N. The 8. 418 effects of Alzheimer's and Parkinson's disease on 28-day mortality of COVID-19. Rev Neurol (Paris). 419 2022;178(1-2):129-36. 420 Hainque E, Grabli D. Rapid worsening in Parkinson's disease may hide COVID-19 infection. 9. 421 Parkinsonism Relat Disord. 2020;75:126-7. 422 Kobylecki C, Jones T, Lim CK, Miller C, Thomson AM. Phenomenology and Outcomes of 10. 423 In-Patients With Parkinson's Disease During the Coronavirus Disease 2019 Pandemic. Mov Disord. 424 2020;35(8):1295-6. 425 Nwabuobi L, Zhang C, Henchcliffe C, Shah H, Sarva H, Lee A, et al. Characteristics and 11. 426 Outcomes of Parkinson's Disease Individuals Hospitalized with COVID-19 in a New York City 427 Hospital System. Mov Disord Clin Pract. 2021;8(7):1100-6. Parihar R, Ferastraoaru V, Galanopoulou AS, Geyer HL, Kaufman DM. Outcome of 12. 428 429 Hospitalized Parkinson's Disease Patients with and without COVID-19. Mov Disord Clin Pract. 430 2021;8(6):859-67. 431 13. Sainz-Amo R, Baena-Álvarez B, Pareés I, Sánchez-Díez G, Pérez-Torre P, López-Sendón JL, et al. COVID-19 in Parkinson's disease: what holds the key? J Neurol. 2021;268(8):2666-70. 432 433 Salari M, Zali A, Ashrafi F, Etemadifar M, Sharma S, Hajizadeh N, et al. Incidence of 14. 434 Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID-19) Pandemic. Mov Disord. 435 2020;35(7):1095-6. 436 Vignatelli L, Zenesini C, Belotti LMB, Baldin E, Bonavina G, Calandra-Buonaura G, et al. 15. 437 Risk of Hospitalization and Death for COVID-19 in People with Parkinson's Disease or Parkinsonism. 438 Mov Disord. 2021:36(1):1-10. 439 16. Xu Y, Surface M, Chan AK, Halpern J, Vanegas-Arroyave N, Ford B, et al. COVID-19 440 manifestations in people with Parkinson's disease: a USA cohort. J Neurol. 2022;269(3):1107-13. Zhai H, Lv Y, Xu Y, Wu Y, Zeng W, Wang T, et al. Characteristic of Parkinson's disease 441 17. 442 with severe COVID-19: a study of 10 cases from Wuhan. J Neural Transm (Vienna). 2021;128(1):37-443 48. 444 18. Zhang Q, Schultz JL, Aldridge GM, Simmering JE, Narayanan NS. Coronavirus Disease 2019 Case Fatality and Parkinson's Disease. Mov Disord. 2020;35(11):1914-5. 445 Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 446 19. 447 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. 448 Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global 449 20. 450 clinical measure of fitness and frailty in elderly people. Cmaj. 2005;173(5):489-95. The ABN Executive in association with subspecialist Advisory Groups. Association of British 451 21. 452 Neurologists Guidance on COVID-19 for people with neurological conditions, their doctors and 453 carers. 2020 9 April 2020. 454 Office for National Statistics. Coronavirus (COVID-19) latest insights: Comparisons 2022 22. [Available from: 455 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/a 456 rticles/coronaviruscovid19latestinsights/overview. 457 458 23. Office for National Statistics. Coronavirus (COVID-19) latest insights: Infections 2022 [Available from: 459 460 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/a rticles/coronaviruscovid19latestinsights/infections. 461 R Development Core Team. R: A language and environment for statistical computing. 462 24. 463 Vienna, Austria: R Foundation for Statistical Computing; 2022. 25. Therneau T. A package for Survival Analysis in R. 3.2-13 ed2021. 464 Brooks ME, Kristensen K, van Benthem KJ, Magnusson A, Berg CW, Nielsen A, et al. 465 26. glmmTMB Balances Speed and Flexibility Among Packages for Zero-inflated Generalized Linear 466 467 Mixed Modeling. The R Journal. 2017;9(2):378-400. Boyes R. Forester: An R package for creating publication-ready forest plots 0.3.0 ed2021. 468 27.

469	28. UK Health Security Agency. Coronavirus (COVID-19) in the UK 2022 [Available from:
470	https://coronavirus.data.gov.uk/details/healthcare.
471	29. Nuffield Department of Population Health. RECOVERY Trial 2023 [Available from:
472	https://www.recoverytrial.net/.
473	30. Parkinson's UK. The prevalence and incidence of Parkinson's in the UK. 2017.
474	31. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al.
475	Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol.
476	2003;157(11):1015-22.
477	32. Scherbaum R, Kwon EH, Richter D, Bartig D, Gold R, Krogias C, et al. Clinical Profiles and
478	Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany. Mov Disord.
479	2021;36(5):1049-57.
480	33. Chaturvedi R, Lui B, Aaronson JA, White RS, Samuels JD. COVID-19 complications in
481	males and females: recent developments. J Comp Eff Res. 2022;11(9):689-98.
482	34. Zhao YJ, Wee HL, Chan YH, Seah SH, Au WL, Lau PN, et al. Progression of Parkinson's
483	disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord. 2010;25(6):710-6.
484	35. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in
485	Parkinson's disease. Mov Disord. 2005;20(10):1255-63.
486	36. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-
487	based study. Brain. 2000;123 (Pt 11):2297-305.
488	37. Blomaard LC, van der Linden CMJ, van der Bol JM, Jansen SWM, Polinder-Bos HA,
489	Willems HC, et al. Frailty is associated with in-hospital mortality in older hospitalised COVID-19
490	patients in the Netherlands: the COVID-OLD study. Age Ageing. 2021;50(3):631-40.
491	38. McMillan JM, Michalchuk Q, Goodarzi Z. Frailty in Parkinson's disease: A systematic review
492	and meta-analysis. Clin Park Relat Disord. 2021;4:100095.
493	39. Ahmed NN, Sherman SJ, Vanwyck D. Frailty in Parkinson's disease and its clinical
494	implications. Parkinsonism Relat Disord. 2008;14(4):334-7.
495	40. Torsney KM, Romero-Ortuno R. The Clinical Frailty Scale predicts inpatient mortality in
496	older hospitalised patients with idiopathic Parkinson's disease. J R Coll Physicians Edinb.
497	2018;48(2):103-7.
498	41. Martí-Pastor A, Moreno-Perez O, Lobato-Martínez E, Valero-Sempere F, Amo-Lozano A,
499	Martínez-García M, et al. Association between Clinical Frailty Scale (CFS) and clinical presentation
500	and outcomes in older inpatients with COVID-19. BMC Geriatr. 2023;23(1):1.
501	42. Andrés-Esteban EM, Quintana-Diaz M, Ramírez-Cervantes KL, Benayas-Peña I, Silva-
502	Obregón A, Magallón-Botaya R, et al. Outcomes of hospitalized patients with COVID-19 according
503	to level of frailty. PeerJ. 2021;9:e11260.
504	43. Aw D, Woodrow L, Ogliari G, Harwood R. Association of frailty with mortality in older
505	inpatients with Covid-19: a cohort study. Age Ageing. 2020;49(6):915-22.
506	44. Wilke V, Sulyok M, Stefanou MI, Richter V, Bender B, Ernemann U, et al. Delirium in
507	hospitalized COVID-19 patients: Predictors and implications for patient outcome. PLoS One.
508	2022;17(12):e0278214.
509	45. White L, Jackson T. Delirium and COVID-19: a narrative review of emerging evidence.
510	Anaesthesia. 2022;77 Suppl 1:49-58.
511	46. Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS, et al. Frequent
512	neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin
513	Transl Neurol. 2020;7(11):2221-30.
514	47. Attia AS, Hussein M, Aboueisha MA, Omar M, Youssef MR, Mankowski N, et al. Altered
515	mental status is a predictor of poor outcomes in COVID-19 patients: A cohort study. PLoS One.
516	2021;16(10):e0258095.
517	48. Kenerly MJ, Shah P, Patel H, Racine R, Jani Y, Owens C, et al. Altered mental status is an
518	independent predictor of mortality in hospitalized COVID-19 patients. Ir J Med Sci. 2022;191(1):21-
519	6.
520	49. Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, et al.
521	Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021;7(1):47.

- 50. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic
 criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689-707; quiz
 837.
- 51. Ritz B, Lee PC, Lassen CF, Arah OA. Parkinson disease and smoking revisited: ease of
 quitting is an early sign of the disease. Neurology. 2014;83(16):1396-402.
- 527 52. Ellis PK, Davies ML, Gray WK, Barber M, Bolnykh I, Sadler M, et al. The Cause and
- 528 Duration of Emergency Admissions to Hospital in People with Idiopathic Parkinson's Disease, Under
- the Care of a UK Service, During the First Year of the COVID-19 Pandemic. J Parkinsons Dis.
 2022;12(6):1833-40.
- 531 53. Scherbaum R, Kwon EH, Richter D, Bartig D, Gold R, Krogias C, et al. Clinical Profiles and
- Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany. Movement Disorders.
 2021;36(5):1049-57.
- 534 54. Gray WK, Navaratnam AV, Day J, Wendon J, Briggs TWR. COVID-19 hospital activity and
- in-hospital mortality during the first and second waves of the pandemic in England: an observationalstudy. Thorax. 2022;77(11):1113-20.
- 537 55. Green S, Perrott SL, McCleary A, Sleeman I, Maple-Grødem J, Counsell CE, et al. First
- delirium episode in Parkinson's disease and parkinsonism: incidence, predictors, and outcomes. NPJ
- 539 Parkinsons Dis. 2021;7(1):92.

540 Supporting information

- 541 **S1** Supporting information. Members of the COVID-19 PD UK study team.
- 542 S2 Supporting information. Tables of summary statistics. Patient, Parkinson's and COVID-19
- 543 characteristics, length of stay and a summary of outcomes.
- 544 **S3 Supporting information. Results of the regression analyses.** Univariable, multivariable and
- sensitivity analyses for the outcomes of mortality, requirement of respiratory support and increase
- 546 in care.
- 547



Daily UK COVID-19 patients admitted to hospital

Frequency of positive COVID-19 tests in COVID-19 PD







Acquired COVID-19 Community Hospital





Figure 4

Variable	N ;	Hazard ratio (95% CI) p-value
Acquired COVID-19 medRxiv preprint doi: https://doi.org/10.1101/2023.04.24.23288 (which was not certified by peer review) is the author/func It is made available unc	9022; this version posted April 25, 2023. The copyright holder for this preprint der, who has granted medRxiv a license to display the preprint in perpetuity. der a C4-bY 4.0 International license.	Reference
Hospital	139	
Age at admission	470	1.10(0.02, 1.04) 0.000
Diagnosis		1.00 (1.00, 1.07)
Parkinson's disease	302	Reference
Parkinson's dementia syndrome		
Atypical parkinsonian syndrome		1 39 (0 74 2 63) 0 306
Ethnicity		1.00 (0.14, 2.00)
White British	401	Reference
Other	69 H	1.24 (0.81, 1.88) 0.327
Sex		
Male	299	Reference
Female	171 Hend	0.54 (0.39, 0.75) <0.001
Wave of COVID-19		
Wave 1	184	1.24 (0.91, 1.7) 0.171
Wave 2	270 🔶	Reference
Other	16 H	- 1.07 (0.43, 2.65) 0.887
Clinical frailty score		
<5	69 Hend	0.62 (0.44, 0.85) 0.004
5-6	227	0.59 (0.33, 1.07) 0.085
7-9	174 •	Reference
Severity of respiratory COVID-19		
Asymptomatic	76 ⊷ ¦	0.22 (0.12, 0.39) <0.001
Mild symptoms	129 🛏	0.27 (0.18, 0.41) <0.001
Respiratory support required	265	Reference
Vaccinated		
No	446 🔶	Reference
Yes	24	0.36 (0.13, 0.99) 0.048
	0.0 1.0 2.0	3.0
	Decreased risk Increa	sed risk

Variable	Ν			Odds Ratio (95% CI) p-	-value
Acquired COVID-19					
Community	175	•			
Hospital	89		—	2.01 (1.10, 3.65) 0.	.022
Age at admission	264			1.01 (0.97, 1.04) 0.	725
Diagnosis					
Parkinson's disease	191	+			
Parkinson's dementia syndrome	e 57	⊢ ●¦		0.84 (0.42, 1.66) 0.	.612
Atypical parkinsonian syndrome	9 16	• • • • • • • • • • • • • • • • • • •		0.99 (0.30, 3.26) 0.	.990
Ethnicity					
White British	225	•			
Other	39			0.70 (0.30, 1.63) 0.4	409
Sex		1			
Male	171	•			
Female	93			1.10 (0.62, 1.95) 0.	745
Wave of COVID-19					
Wave 1	66			1.61 (0.84, 3.09) 0.	154
Wave 2	195	•			
Other	3	•		0.22 (0.01, 3.67) 0.	.290
Delirium					
No	176	+			
Yes	88		•	2.07 (1.48, 3.86) 0.	.006
		0.0 1.0 2.	0 3.0 4.0	5.0	
		Decreased odds	Incre	eased odds	

Variable	Ν				0	Odds Ratio (95% CI)	p-value
Acquired COVID-19								
Community	372	∳						
Hospital	163	Here i				0.54 (0.36, 0	0.81)	0.003
Age at admission	535	•				1.00 (0.98, 1	1.02)	0.850
Diagnosis								
Parkinson's disease	339	•						
Parkinson's dementia syndrom	e 163	⊢ e ¦ →				0.93 (0.61, 1	1.41)	0.731
Atypical parkinsonian syndrome	e 33	·+	•			1.88 (0.83, 4	4.23)	0.128
Ethnicity								
White British	463	•						
Other	72		-			0.90 (0.51, 1	1.61)	0.733
Sex		1						
Male	352	+						
Female	183					0.94 (0.64, 1	1.39)	0.765
Wave of COVID-19								
Wave 1	184		•			1.50 (0.98, 2	2.29)	0.060
Wave 2	333	•						
Other	18	· • ;				0.71 (0.26, 1	1.98)	0.513
Chronic neurological disorder								
No	455	+						
Yes	80		•			1.81 (1.06, 3	3.09)	0.031
		0.0 1.0	2.0	3.0	4.0	-		
		Decreased odds		Increa	ased odds	5		